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Supplementary data
Supplemental Materials
Human IgG1 mAbs directed to HLA ( Supplementary Table S1 ) were produced by hybridoma technology as previously described, 1 and purified using protein A. Antibodies directed to CD62P (clone AK-4), C3b/iC3b (clone 3E7/C3b), CD41 (clone HIP8) and human IgG Fc (clone HP60717) were obtained from BioLegend (San Diego, CA, USA). Anti-C5b-9 (A227) was from Complement Technology (Tyler, TX, USA). Anti-CD42a (clone ALMA.16) was from BD Biosciences (San Jose, CA, USA). Blocking antibody anti-CD32a (clone IV.3) was from Bio X Cell (West Lebanon, NH, USA). Syk inhibitor IV (BAY 61-3606) was obtained from Merck (Kenilworth, NJ, USA). Monoclonal anti-C5 antibody Eculizumab was from Alexion Pharmaceuticals (New Haven, CT, USA). Monoclonal blocking antibody anti-C1q-85 has been described before, 2, 3 Anti-C4 antibody clone C4-10 4 was from B51  B44  B47  A34  B53  B45  B48  A36  B59  B47  B50  A43  B78  B48  B51  A66  B49  B53  A68  B50  B54  A69  B51  B55  A80  B52  B56  B53  B57  B57  B58  B58  B60  B59  B62  B73  B70  B81  B75  B76  B78 
